/

Società

No

Non verificato

Novo Nordisk

Di cosa scriviamo

Cronaca BiancaCronaca Rosa / GossipFitnessMedicina - VarieSalute

5 comunicati stampa

Guarda tutti i comunicati

11/07/2026

Salute

Fitness

Cronaca Rosa / Gossip

Cronaca Bianca

Medicina - Varie

Novo Nordisk's denecimig (Mim8) demonstrated positive results in long term safety and efficacy in phase 3 hemophilia A FRONTIER extension study at ISTH 2026

Fonte

Emittente

1.00

0

Press Release cover image

26/06/2026

Salute

Fitness

Cronaca Rosa / Gossip

Cronaca Bianca

Medicina - Varie

Ecologia/Salute ambientale

Agricoltura

Novo Nordisk to showcase new data across its hemophilia portfolio at the ISTH Congress 2026, featuring investigational denecimig

Fonte

Emittente

1.00

0

Press Release cover image

06/06/2026

Cronaca Rosa / Gossip

Cronaca Bianca

People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data

Fonte

Emittente

1.00

0

Press Release cover image

29/04/2026

Salute

Fitness

Medicina - Varie

Denecimig (Mim8) significantly reduced annualized bleeding rate in people with hemophilia A, regardless of inhibitor status, in phase 3 data published in NEJM

Fonte

Emittente

1.00

0

Press Release cover image

01/04/2026

Salute

Fitness

Medicina - Varie

Wegovy®▼(semaglutide injection) 2.4 mg recommended by NICE to reduce risk of major adverse cardiovascular events, including heart attacks and strokes, in adults with established cardiovascular disease and overweight or obesity (BMI ≥27 kg/m2)[1]

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0